Abstract
Prostate cancer is the most prevalent tumor in the male population and the second leading cause of cancerrelated death in men in Western countries. Besides genetic and epigenetic aberrations in protein coding genes, alterations in microRNAs equally contribute to prostate cancer initiation and progression. In this context, a plethora of overwhelming evidence establishes the involvement of microRNAs as essential actors in the multi-step cascade fostering a prostate cancer cell to leave the primary tumor and form secondary tumors at distant sites. Herein, we describe how specific microRNAs may impinge on the different stages of prostate cancer metastasis and review published profiling studies in which microRNA expression data have been analyzed in relation to clinical parameters of progression for the identification of novel biomarkers. We also provide evidence concerning the possibility to manipulate metastasis-related microRNA functions, either by mimicking or inhibiting them, as a highly promising strategy for the development of innovative therapeutic approaches for the advanced disease.
Keywords: Antagomir, circulating miRNA, LNA, metastasis, microRNA, prognosis, prostate cancer, therapy
Current Medicinal Chemistry
Title:MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets
Volume: 20 Issue: 12
Author(s): Nicola Fenderico, Anna Casamichele, Valentina Profumo, Nadia Zaffaroni and Paolo Gandellini
Affiliation:
Keywords: Antagomir, circulating miRNA, LNA, metastasis, microRNA, prognosis, prostate cancer, therapy
Abstract: Prostate cancer is the most prevalent tumor in the male population and the second leading cause of cancerrelated death in men in Western countries. Besides genetic and epigenetic aberrations in protein coding genes, alterations in microRNAs equally contribute to prostate cancer initiation and progression. In this context, a plethora of overwhelming evidence establishes the involvement of microRNAs as essential actors in the multi-step cascade fostering a prostate cancer cell to leave the primary tumor and form secondary tumors at distant sites. Herein, we describe how specific microRNAs may impinge on the different stages of prostate cancer metastasis and review published profiling studies in which microRNA expression data have been analyzed in relation to clinical parameters of progression for the identification of novel biomarkers. We also provide evidence concerning the possibility to manipulate metastasis-related microRNA functions, either by mimicking or inhibiting them, as a highly promising strategy for the development of innovative therapeutic approaches for the advanced disease.
Export Options
About this article
Cite this article as:
Fenderico Nicola, Casamichele Anna, Profumo Valentina, Zaffaroni Nadia and Gandellini Paolo, MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets, Current Medicinal Chemistry 2013; 20 (12) . https://dx.doi.org/10.2174/0929867311320120007
DOI https://dx.doi.org/10.2174/0929867311320120007 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Receptors of Extracellular Matrix Molecules
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Current Genomics Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma
Current Radiopharmaceuticals Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Of Humans and Hamsters: The Hamster Buccal Pouch Carcinogenesis Model as a Paradigm for Oral Oncogenesis and Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone/Acylhydrazone Scaffolds
Current Topics in Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry Astrocytic Signaling in Persistent Pain
Current Signal Transduction Therapy Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews Negative Glucocorticoid Receptor Response Elements and their Role in Glucocorticoid Action
Current Pharmaceutical Design In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening